According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “
A number of other research analysts have also issued reports on TRIL. JMP Securities started coverage on Trillium Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $10.00 target price for the company. BidaskClub cut Trillium Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, ValuEngine upgraded Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, April 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.13.
TRIL opened at $6.68 on Thursday. Trillium Therapeutics has a 52 week low of $0.24 and a 52 week high of $9.66. The business has a fifty day simple moving average of $7.84 and a 200-day simple moving average of $5.52.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.14). Equities research analysts predict that Trillium Therapeutics will post -0.76 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of the stock. Tekla Capital Management LLC increased its position in Trillium Therapeutics by 0.4% in the 1st quarter. Tekla Capital Management LLC now owns 448,049 shares of the biotechnology company’s stock valued at $1,810,000 after acquiring an additional 1,950 shares during the period. Lindbrook Capital LLC purchased a new stake in shares of Trillium Therapeutics during the 1st quarter worth approximately $40,000. UBS Group AG purchased a new stake in shares of Trillium Therapeutics during the 1st quarter worth approximately $46,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Trillium Therapeutics during the 2nd quarter worth approximately $95,000. Finally, Creative Planning purchased a new stake in shares of Trillium Therapeutics during the 2nd quarter worth approximately $99,000. Hedge funds and other institutional investors own 72.53% of the company’s stock.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Article: Certificate of Deposit (CD) For Risk Adverse Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.